Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECMC-GART: Molecular vs Conventional Risk Stratification in Endometrial Cancer
NCT05524389Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2026
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Loco-regional recurrence rate at 3 years. Planned start Dec 2022; status: not yet recruiting.
Beyond the preview
Go deeper on NCT05524389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524389.